Monte Rosa Therapeutics (GLUE) stock: insider trades, news & valuation
Heavy selling
Close · Oct 9, 2026
$10.30
-0.2% on the day
+21.7% over 12 months
52-week range $8.46 – $25.31
Share price and insider trades
GLUE closeInsider buyInsider sale
Bought, 12 months$0
Sold, 12 months$4.1M
Insiders buying0
Insiders selling8
Monte Rosa Therapeutics insider trading at a glance (Oct 9, 2026): in the past 12 months, 0 insiders bought $0 and 8 sold $4.1M of GLUE stock on the open market.
Get emailed when insiders cluster-buy stocks like GLUE
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
GLUE insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | $137 | 1 |
| Q3 2026 | — | 0 | $462K | 4 |
| Q2 2026 | — | 0 | $2.4M | 18 |
| Q1 2026 | — | 0 | $1.2M | 14 |
Valuation, profit and volume
P/E (trailing)n/aSector median —
Market value—
Profit margin—Revenue growth —
Volume vs. 50-day1.2×Last 5 sessions
Insiders' paper profit—On all tracked purchases —
Summary
Over the past 12 months, 0 Monte Rosa Therapeutics, Inc. insiders reported open-market purchases totaling $0, while 8 insiders reported sales totaling $4.1M. 21 of 37 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Oct 6SEC | Matthew BowenPrincipal Accounting Officer | Sell | 1325,891 held (−0%) | $10.56 | $137 | -2.5% | — |
| Jul 17SEC | Markus WarmuthCEO, President | Sell | 9,500585,038 held (−2%) | $23.18 | $220K | -55.6% | — |
| Jul 16SEC | Jennifer ChampouxCOO | Sell Plan | 4,35162,371 held (−7%) | $23.38 | $102K | -55.9% | — |
| Jul 7SEC | Sharon TownsonChief Scientific Officer | Sell Plan | 5,60068,245 held (−8%) | $23.25 | $130K | -55.7% | — |
| Jul 7SEC | Sharon TownsonChief Scientific Officer | Sell Plan | 40067,845 held (−1%) | $24.13 | $10K | -57.3% | — |
| Jul 1SEC | Filip JankuChief Medical Officer | Sell Plan | 5,40760,612 held (−8%) | $24.50 | $132K | -58.0% | — |
| Jun 30SEC | Anthony M. ManningDirector | Sell | 10,000 | $23.11 | $231K | -55.4% | — |
| Jun 30SEC | Filip JankuChief Medical Officer | Sell Plan | 6,00059,992 held (−9%) | $22.95 | $138K | -55.1% | — |
| Jun 25SEC | Filip JankuChief Medical Officer | Sell Plan | 30,00059,992 held (−33%) | $21.42 | $643K | -51.9% | — |
| Jun 25SEC | Filip JankuChief Medical Officer | Sell Plan | 11,84559,992 held (−16%) | $20.22 | $240K | -49.1% | — |
| Jun 25SEC | Sharon TownsonChief Scientific Officer | Sell Plan | 3,00067,845 held (−4%) | $20.00 | $60K | -48.5% | — |
| Jun 25SEC | Jennifer ChampouxCOO | Sell Plan | 2,17562,371 held (−3%) | $20.00 | $44K | -48.5% | — |
| Jun 18SEC | Sharon TownsonChief Scientific Officer | Sell Plan | 3,00067,845 held (−4%) | $19.00 | $57K | -45.8% | — |
| Jun 18SEC | Jennifer ChampouxCOO | Sell Plan | 2,17662,371 held (−3%) | $19.00 | $41K | -45.8% | — |
| Jun 2SEC | Markus WarmuthCEO, President | Sell Plan | 4,998595,006 held (−1%) | $19.41 | $97K | -46.9% | — |
| Jun 2SEC | Markus WarmuthCEO, President | Sell Plan | 468594,538 held (−0%) | $19.73 | $9K | -47.8% | — |
| Jun 1SEC | Sharon TownsonChief Scientific Officer | Sell Plan | 6,00067,845 held (−8%) | $19.87 | $119K | -48.2% | — |
| May 28SEC | Jennifer ChampouxCOO | Sell Plan | 2,17562,371 held (−3%) | $20.00 | $44K | -48.5% | — |
| May 26SEC | Jennifer ChampouxCOO | Sell Plan | 2,17662,371 held (−3%) | $19.00 | $41K | -45.8% | — |
| May 22SEC | Anthony M. ManningDirector | Sell | 10,000 | $18.01 | $180K | -42.8% | — |
| May 5SEC | Markus WarmuthCEO, President | Sell Plan | 5,467600,004 held (−1%) | $18.92 | $103K | -45.6% | — |
| Apr 15SEC | Markus WarmuthCEO, President | Sell | 8,000605,471 held (−1%) | $17.64 | $141K | -41.6% | — |
| Apr 10SEC | Philip NicksonChief Business & Legal Officer | Sell | 5,84555,000 held (−10%) | $17.69 | $103K | -41.8% | — |
| Mar 5SEC | Edmund DunnPrincipal Accounting Officer | Sell | 13922,554 held (−1%) | $17.96 | $2K | -42.7% | — |
| Mar 4SEC | Markus WarmuthCEO, President | Sell Plan | 5,466613,471 held (−1%) | $17.92 | $98K | -42.5% | — |
| Mar 2SEC | Edmund DunnPrincipal Accounting Officer | Sell | 25,16422,693 held (−53%) | $18.10 | $455K | -43.1% | — |
| Mar 2SEC | Edmund DunnPrincipal Accounting Officer | Sell | 53622,693 held (−2%) | $17.50 | $9K | -41.1% | — |
| Feb 24SEC | Filip JankuChief Medical Officer | Sell | 9,18965,837 held (−12%) | $19.50 | $179K | -47.2% | — |
| Jan 9SEC | Markus WarmuthCEO, President | Sell Plan | 3,707620,696 held (−1%) | $23.24 | $86K | -55.7% | — |
| Jan 9SEC | Markus WarmuthCEO, President | Sell Plan | 1,450619,246 held (−0%) | $23.88 | $35K | -56.9% | — |
| Jan 9SEC | Markus WarmuthCEO, President | Sell Plan | 309618,937 held (−0%) | $24.57 | $8K | -58.1% | — |
| Jan 5SEC | Markus WarmuthCEO, President | Sell | 10,135624,403 held (−2%) | $15.17 | $154K | -32.1% | — |
| Jan 5SEC | Philip NicksonChief Business & Legal Officer | Sell | 3,15560,845 held (−5%) | $15.17 | $48K | -32.1% | — |
| Jan 5SEC | Sharon TownsonChief Scientific Officer | Sell | 3,15567,845 held (−4%) | $15.17 | $48K | -32.1% | — |
| Jan 5SEC | Filip JankuChief Medical Officer | Sell | 3,15575,026 held (−4%) | $15.17 | $48K | -32.1% | — |
| Jan 5SEC | Jennifer ChampouxCOO | Sell | 2,62962,371 held (−4%) | $15.17 | $40K | -32.1% | — |
| Jan 5SEC | Edmund DunnPrincipal Accounting Officer | Sell | 1,03922,693 held (−4%) | $15.17 | $16K | -32.1% | — |
Insiders at Monte Rosa Therapeutics, Inc.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Filip JankuChief Medical Officer | — | $1.4M | Jul 1, 2026 | — |
| Markus WarmuthCEO, President | — | $951K | Jul 17, 2026 | — |
| Edmund DunnPrincipal Accounting Officer | — | $483K | Mar 5, 2026 | — |
| Sharon TownsonChief Scientific Officer | — | $424K | Jul 7, 2026 | — |
| Anthony M. ManningDirector | — | $411K | Jun 30, 2026 | — |
| Jennifer ChampouxCOO | — | $311K | Jul 16, 2026 | — |
| Philip NicksonChief Business & Legal Officer | — | $151K | Apr 10, 2026 | — |
| Matthew BowenPrincipal Accounting Officer | — | $137 | Oct 6, 2026 | — |
GLUE stock: common questions
Are Monte Rosa Therapeutics, Inc. insiders buying GLUE stock?
In the past 12 months, 0 insiders reported open-market purchases of GLUE worth $0.
Are Monte Rosa Therapeutics, Inc. insiders selling GLUE stock?
8 insiders reported sales worth $4.1M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is GLUE's 52-week range?
Over the past year GLUE has traded between $8.46 and $25.31. It last closed at $10.30 on Oct 9, 2026.